ArticleCold Spring Harbor molecular case studies2020
Clinical report: one year of treatment of Proteus syndrome with miransertib (ARQ 092).
Article in Cold Spring Harbor molecular case studies, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 41 citations in OpenAlex.
- Safety findings from the phase 1/2 MOSAIC study of miransertib for patients with PIK3CA-related overgrowth spectrum or Proteus syndrome.Orphanet journal of rare diseases · 2025Trial
- Development and validation of an LC-MS/MS assay for the quantification of Miransertib in human plasma and clinical application.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2026Article
- Deciphering the Medicinal Chemistry Aspects of Akt Inhibitors for the Management of Cancer: Structure-Activity Relationship Frameworks, Landscapes, and Optimization Approaches.Chemistry & biodiversity · 2026Review
- Characterizing Paratesticular Neoplasms in Proteus Syndrome.The American journal of surgical pathology · 2026Article
- mTOR pathway diseases: challenges and opportunities from bench to bedside and the mTOR node.Orphanet journal of rare diseases · 2025Review
- Venous Malformations: Unraveling Latest Mechanisms and Bridging Gaps in Targeted Therapy Development.International journal of biological sciences · 2025Review
- Proteus syndrome with late diagnosis confirmation: a case report.Frontiers in pediatrics · 2025Article
- Human vascular organoids with a mosaicbioRxiv : the preprint server for biology · 2024Article
- Multimodal ocular imaging in Proteus syndrome.European journal of ophthalmology · 2023Article
- How we approach the use of sirolimus and new agents: Medical therapy to treat vascular anomalies.Pediatric blood & cancer · 2022Article
- When, where and which PIK3CA mutations are pathogenic in congenital disorders.Nature cardiovascular research · 2022Review
- The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib.EMBO molecular medicine · 2022Article
- Postmortem Diagnosis of the Proteus Syndrome by Next Generation Sequencing of Affected Brain Tissue.Academic forensic pathology · 2022Article
- Development of the Clinical Gestalt Assessment: a visual clinical global impression scale for Proteus syndrome.Orphanet journal of rare diseases · 2022Article
- Emerging Roles for Mammalian Target of Rapamycin (mTOR) Complexes in Bladder Cancer Progression and Therapy.Cancers · 2022Review
- On drug discovery against infectious diseases and academic medicinal chemistry contributions.Beilstein journal of organic chemistry · 2022Article
- Case report: five-year experience of AKT inhibition with miransertib (MK-7075) in an individual with Proteus syndrome.Cold Spring Harbor molecular case studies · 2021Article
- Acetylsalicylic acid suppression of the PI3K pathway as a novel medical therapy for head and neck lymphatic malformations.International journal of pediatric otorhinolaryngology · 2021Article
- Functional and structural analyses of novel Smith-Kingsmore Syndrome-Associated MTOR variants reveal potential new mechanisms and predictors of pathogenicity.PLoS genetics · 2021Article
- Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review.Medical oncology (Northwood, London, England) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
A 20-yr-old man with Proteus syndrome (PS) and somatic mosaicism of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.